Global Antibody and Recombinant Protein CDMO Market Outlook , 2030

2024

Global Antibody and Recombinant Protein CDMO Market Outlook , 2030

Name: Global Antibody and Recombinant Protein CDMO Market Outlook , 2030
Brand: Bonafide Research
SKU: 95001089
Price: 3450 USD
Availability: InStock
Rating: 4 (11.15 reviews)

The Global Antibody and Recombinant Protein CMDO Market is projected to grow at over 7.39% CAGR by 2030, driven by advancements in biopharmaceutical manufacturing and contract serv

Bonafide Trust
29-06-2024
Pages : 153
Figures : 79
Tables : 165
Region : Global
Category : Lifescience & Healthcare
Healthcare

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The Global Antibody and Recombinant Protein Contract Development and Manufacturing Organisation (CDMO) market is a fast-growing segment of the biopharmaceutical industry, driven by rising demand for improved treatments and biotechnological advancements. This market includes services offered by CDMOs that specialise in the development and manufacture of antibodies and recombinant proteins, which are critical components in a variety of therapeutic and diagnostic applications. The early 2000s saw a spike in biopharmaceutical R&D, resulting in increased demand for high-quality biologics. This need has fuelled the establishment of CDMOs that specialise in antibody and recombinant protein manufacturing. The market expanded with the introduction of sophisticated expression systems like as CHO (Chinese Hamster Ovary) cells and E. coli, which enabled higher yields and improved product quality. The antibody and recombinant protein CDMO market is highly regulated, with severe guidelines established by regulatory authorities such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. These regulations address many areas of biologics development and manufacture, such as Good manufacture Practices (GMP), quality control, and clinical trial requirements .In recent years, there has been an increased emphasis on regulatory harmonisation to expedite approval processes across regions. This trend is especially favourable for CDMOs operating on a worldwide scale because it facilitates market access and minimises the burden of negotiating multiple regulatory environments.

According to the research report "Global Antibody and Recombinant Protein CMDO Market Overview, 2030 " published by Bonafide Research, the Global antibody and recombinant protein CMDO market is anticipated to grow at more than 7.39% CAGR from 2024 to 2030. Innovation is a major driver of growth in the antibody and recombinant protein CDMO markets. The introduction of modern technology, such as single-use bioreactors, continuous bioprocessing, and automation, has dramatically increased production efficiency while decreasing prices. Continuous bioprocessing, which involves the continuous flow of materials through the manufacturing process, is another growing technology with various benefits, including enhanced productivity, a smaller environmental imprint, and higher product quality. Furthermore, innovations in cell line engineering, such as CRISPR/Cas9 gene editing and synthetic biology, are allowing the generation of high-yield, high-productivity cell lines, which is propelling market expansion. The global antibody and recombinant protein CDMO market is extremely competitive, with a few prominent manufacturers dominating the field. Lonza Group, for example, is well-known for its broad service portfolio, which includes cell line creation, process development, and commercial manufacturing. Samsung Biologics and WuXi Biologics have emerged as key participants thanks to their cutting-edge facilities, powerful technology platforms, and strong emphasis on innovation. Other noteworthy players include Catalent, which manufactures pharmacological substances and products, as well as Boehringer Ingelheim, which specialises in microbial and mammalian cell culture techniques.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamics
Market Drivers

Therapeutic Applications: Biologics, particularly monoclonal antibodies and recombinant proteins, are critical in the treatment of chronic diseases like cancer, autoimmune disorders, and infections. The success of these biologics in targeting specific molecules has resulted in rising demand.
Growing Biopharmaceutical R&D Investments: The biopharmaceutical industry invests heavily in research and development with the goal of discovering and developing new biologics. This tendency drives up the demand for CDMO services to support clinical studies and commercial production.
Innovative Manufacturing Techniques: The introduction of new technologies such as single-use bioreactors, continuous processing, and automation has increased the efficiency, flexibility, and cost-effectiveness of antibody and recombinant protein manufacturing.

Market Challenges

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Technical Challenges: Antibodies and recombinant proteins are produced using sophisticated methods such as cell line creation, fermentation, purification, and formulation. The variability of biological systems can make it difficult to achieve consistent quality and productivity.

High Cost of Production: Production expenses are significant due to the complex equipment and knowledge necessary for biologics manufacture. This can be a substantial hurdle, particularly for small businesses and startups with little resources.
IP (Intellectual Property) Management: Protecting intellectual property rights while engaging with various partners in the CDMO space can be challenging. Disputes over intellectual property ownership and licensing can cause delays in product development and commercialisation efforts.

Market Trends

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

End-to-End Solutions: CDMOs are expanding their service offerings to include early-stage development and commercial-scale manufacturing. This integrated approach appeals to biopharmaceutical businesses seeking streamlined, cost-effective market access.
Specialised Services: There is an increasing demand for specialised services, such as high-throughput screening, advanced analytical services, and custom cell line generation, to meet the unique needs of biologics research.
Innovative Biologics: Next-generation biologics such as bispecific antibodies, antibody-drug conjugates (ADCs), and fusion proteins are gaining popularity. These complicated compounds necessitate specialised knowledge and modern technologies, resulting in increased demand for CDMO services.

Segmentation Analysis
Based on the report, the type is segmented into Antibody CDMO and Recombinant Protein CDMO
Antibody CDMO services specialise in the development and manufacturing of monoclonal antibodies (mAbs), polyclonal antibodies, and new antibody formats such as bispecific antibodies and antibody-drug conjugates (ADCs). This category is dominating the market due to increased demand for monoclonal antibodies, which are highly selective, effective in treating diseases such as cancer, autoimmune disorders, and infectious diseases, and have less adverse effects than typical small-molecule medications. The monoclonal antibody segment has grown at an exponential rate, owing to its success in immuno-oncology and other targeted therapeutics. CDMOs specialising in antibodies provide comprehensive services such as cell line creation, process optimisation, scale-up, and commercial production, allowing biopharmaceutical companies to fulfil the growing demand for these biologics. Recombinant Protein CDMO services, on the other hand, focus on the creation and production of recombinant proteins such as enzymes, hormones, cytokines, and growth factors for use in a variety of therapeutic and industrial applications. While this area is likewise rapidly expanding, it lags behind the antibody CDMO segment. Recombinant proteins are widely employed in medicinal applications, particularly hormone replacement therapy and biosimilars. However, due to their more restricted applications, these proteins have a lesser market demand than monoclonal antibodies, making this group the second-largest.

Based on the report, the type is segmented into Pharmaceutical Company, Biotechnology Company, Generic Company.

Biotechnology businesses are the pioneers in the usage of antibody and recombinant protein CDMO services. This is because biotech companies are increasingly focused on innovation and heavily invested in generating innovative biologics, necessitating the specialised development capabilities that CDMOs offer. Their reliance on CDMOs for flexible, scalable, and cost-effective solutions distinguishes them as the market's leading category. Pharmaceutical companies use CDMO services largely for the research and large-scale production of monoclonal antibodies and recombinant proteins, which are critical to their new medication pipelines. These firms specialise in developing innovative biologic medicines for oncology, immunology, and rare disorders. Pharmaceutical businesses that outsource to CDMOs gain access to specialised expertise, modern technologies, and cutting-edge facilities. Generic businesses generally use CDMO services to research and produce biosimilars, which are generic versions of biologics whose patents have expired. The recombinant protein segment is especially important for these companies since it replicates medicinal proteins like hormones and enzymes. However, due to the strict regulatory requirements and complexity of biologics production, specialised CDMO services are required to ensure quality and compliance.

Regional Analysis
North America and Asia-Pacific are both leading regions in the global antibody and recombinant protein CDMO market.

North America leads the antibody and recombinant protein CDMO industry, with the United States serving as a biopharmaceutical innovation engine. The region has a well-established pharmaceutical and biotechnology industry, advanced healthcare infrastructure, and major investments in R&D. The increased prevalence of chronic diseases such as cancer and autoimmune disorders has resulted in an increase in demand for biologics in North America, notably monoclonal antibodies and recombinant proteins. Lonza, Catalent, Inc., and Boehringer Ingelheim are prominent participants in North America, providing comprehensive CDMO services spanning from cell line creation to large-scale manufacture. The Asia-Pacific area is emerging as an important destination for biopharmaceutical outsourcing due to the growing emphasis on biosimilars, which is driven by the expiration of biologic patents and the demand for cost-effective medicines. Governments in China and India are aggressively supporting the biopharmaceutical industry with favourable regulations, financial initiatives, and infrastructure development. Innovations such as sophisticated expression systems (e.g., CHO cells) and the incorporation of artificial intelligence and machine learning into bioprocessing are generating substantial growth in the region. Leading CDMOs in the region, including WuXi Biologics, Samsung Biologics, and Fujifilm Diosynth Biotechnologies, are investing extensively in expanding their manufacturing capacity and capabilities to meet the growing demand for biologics.

Key Development
• In December 2023, Fujifilm Diosynth Biotechnologies announced the extension of its CDMO capabilities to encompass gene therapy vector production in the United States and the United Kingdom. This move is noteworthy since it broadens their service offerings to encompass not only antibodies and recombinant proteins but also sophisticated medicines.
• In November 2023, Boehringer Ingelheim begins building of a new biologics production facility in Austria. This facility is planned to be operational by 2026, increasing the company's capacity to produce biologics such as monoclonal antibodies and recombinant proteins.
• In March 2024, WuXi Biologics, a major player in the CDMO industry, made a large investment in a new cutting-edge production plant in Ireland. This facility will specialise in the synthesis of antibodies and recombinant proteins, expanding WuXi's global reach and providing complete solutions from early development to commercial manufacturing.
• In February 2024, Samsung Biologics introduced a new single-use bioreactor technology at its South Korean manufacturing location. This idea aims to improve manufacturing flexibility and reduce contamination hazards, ultimately increasing the efficiency and scalability of biologics production.

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antibody and Recombinant Protein CDMO Market Size 2019-2030
2.1.2 Antibody and Recombinant Protein CDMO Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Antibody and Recombinant Protein CDMO Segment by Type
2.2.1 Antibody CDMO
2.2.2 Recombinant Protein CDMO
2.3 Antibody and Recombinant Protein CDMO Market Size by Type
2.3.1 Antibody and Recombinant Protein CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
2.4 Antibody and Recombinant Protein CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Biotechnology Company
2.4.3 Generic Company
2.5 Antibody and Recombinant Protein CDMO Market Size by Application
2.5.1 Antibody and Recombinant Protein CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
3 Antibody and Recombinant Protein CDMO Market Size by Player
3.1 Antibody and Recombinant Protein CDMO Market Size Market Share by Players
3.1.1 Global Antibody and Recombinant Protein CDMO Revenue by Players (2019-2024)
3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Antibody and Recombinant Protein CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Antibody and Recombinant Protein CDMO by Regions
4.1 Antibody and Recombinant Protein CDMO Market Size by Regions (2019-2024)
4.2 Americas Antibody and Recombinant Protein CDMO Market Size Growth (2019-2024)
4.3 APAC Antibody and Recombinant Protein CDMO Market Size Growth (2019-2024)
4.4 Europe Antibody and Recombinant Protein CDMO Market Size Growth (2019-2024)
4.5 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Growth (2019-2024)
5 Americas
5.1 Americas Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024)
5.2 Americas Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)
5.3 Americas Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024)
6.2 APAC Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)
6.3 APAC Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Antibody and Recombinant Protein CDMO by Country (2019-2024)
7.2 Europe Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antibody and Recombinant Protein CDMO by Region (2019-2024)
8.2 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024)
8.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Antibody and Recombinant Protein CDMO Market Forecast
10.1 Global Antibody and Recombinant Protein CDMO Forecast by Regions (2025-2030)
10.1.1 Global Antibody and Recombinant Protein CDMO Forecast by Regions (2025-2030)
10.1.2 Americas Antibody and Recombinant Protein CDMO Forecast
10.1.3 APAC Antibody and Recombinant Protein CDMO Forecast
10.1.4 Europe Antibody and Recombinant Protein CDMO Forecast
10.1.5 Middle East & Africa Antibody and Recombinant Protein CDMO Forecast
10.2 Americas Antibody and Recombinant Protein CDMO Forecast by Country (2025-2030)
10.2.1 United States Antibody and Recombinant Protein CDMO Market Forecast
10.2.2 Canada Antibody and Recombinant Protein CDMO Market Forecast
10.2.3 Mexico Antibody and Recombinant Protein CDMO Market Forecast
10.2.4 Brazil Antibody and Recombinant Protein CDMO Market Forecast
10.3 APAC Antibody and Recombinant Protein CDMO Forecast by Region (2025-2030)
10.3.1 China Antibody and Recombinant Protein CDMO Market Forecast
10.3.2 Japan Antibody and Recombinant Protein CDMO Market Forecast
10.3.3 Korea Antibody and Recombinant Protein CDMO Market Forecast
10.3.4 Southeast Asia Antibody and Recombinant Protein CDMO Market Forecast
10.3.5 India Antibody and Recombinant Protein CDMO Market Forecast
10.3.6 Australia Antibody and Recombinant Protein CDMO Market Forecast
10.4 Europe Antibody and Recombinant Protein CDMO Forecast by Country (2025-2030)
10.4.1 Germany Antibody and Recombinant Protein CDMO Market Forecast
10.4.2 France Antibody and Recombinant Protein CDMO Market Forecast
10.4.3 UK Antibody and Recombinant Protein CDMO Market Forecast
10.4.4 Italy Antibody and Recombinant Protein CDMO Market Forecast
10.4.5 Russia Antibody and Recombinant Protein CDMO Market Forecast
10.5 Middle East & Africa Antibody and Recombinant Protein CDMO Forecast by Region (2025-2030)
10.5.1 Egypt Antibody and Recombinant Protein CDMO Market Forecast
10.5.2 South Africa Antibody and Recombinant Protein CDMO Market Forecast
10.5.3 Israel Antibody and Recombinant Protein CDMO Market Forecast
10.5.4 Turkey Antibody and Recombinant Protein CDMO Market Forecast
10.5.5 GCC Countries Antibody and Recombinant Protein CDMO Market Forecast
10.6 Global Antibody and Recombinant Protein CDMO Forecast by Type (2025-2030)
10.7 Global Antibody and Recombinant Protein CDMO Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Batavia Biosciences
11.1.1 Batavia Biosciences Company Information
11.1.2 Batavia Biosciences Antibody and Recombinant Protein CDMO Product Offered
11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Batavia Biosciences Main Business Overview
11.1.5 Batavia Biosciences Latest Developments
11.2 Grifols
11.2.1 Grifols Company Information
11.2.2 Grifols Antibody and Recombinant Protein CDMO Product Offered
11.2.3 Grifols Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Grifols Main Business Overview
11.2.5 Grifols Latest Developments
11.3 Cerbios-Pharma SA
11.3.1 Cerbios-Pharma SA Company Information
11.3.2 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Offered
11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Cerbios-Pharma SA Main Business Overview
11.3.5 Cerbios-Pharma SA Latest Developments
11.4 HALIX
11.4.1 HALIX Company Information
11.4.2 HALIX Antibody and Recombinant Protein CDMO Product Offered
11.4.3 HALIX Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 HALIX Main Business Overview
11.4.5 HALIX Latest Developments
11.5 Biovian Oy
11.5.1 Biovian Oy Company Information
11.5.2 Biovian Oy Antibody and Recombinant Protein CDMO Product Offered
11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Biovian Oy Main Business Overview
11.5.5 Biovian Oy Latest Developments
11.6 Catalent
11.6.1 Catalent Company Information
11.6.2 Catalent Antibody and Recombinant Protein CDMO Product Offered
11.6.3 Catalent Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Catalent Main Business Overview
11.6.5 Catalent Latest Developments
11.7 Goodwin Biotechnology
11.7.1 Goodwin Biotechnology Company Information
11.7.2 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product Offered
11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Goodwin Biotechnology Main Business Overview
11.7.5 Goodwin Biotechnology Latest Developments
11.8 Merck
11.8.1 Merck Company Information
11.8.2 Merck Antibody and Recombinant Protein CDMO Product Offered
11.8.3 Merck Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Merck Main Business Overview
11.8.5 Merck Latest Developments
11.9 Hangzhou Hs-biopharm
11.9.1 Hangzhou Hs-biopharm Company Information
11.9.2 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product Offered
11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Hangzhou Hs-biopharm Main Business Overview
11.9.5 Hangzhou Hs-biopharm Latest Developments
11.10 Wuxibiologics
11.10.1 Wuxibiologics Company Information
11.10.2 Wuxibiologics Antibody and Recombinant Protein CDMO Product Offered
11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Wuxibiologics Main Business Overview
11.10.5 Wuxibiologics Latest Developments
11.11 Bioinnobio
11.11.1 Bioinnobio Company Information
11.11.2 Bioinnobio Antibody and Recombinant Protein CDMO Product Offered
11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Bioinnobio Main Business Overview
11.11.5 Bioinnobio Latest Developments
11.12 Thousand Oaks Biopharmaceuticals
11.12.1 Thousand Oaks Biopharmaceuticals Company Information
11.12.2 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product Offered
11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Thousand Oaks Biopharmaceuticals Main Business Overview
11.12.5 Thousand Oaks Biopharmaceuticals Latest Developments
11.13 Eurogentec
11.13.1 Eurogentec Company Information
11.13.2 Eurogentec Antibody and Recombinant Protein CDMO Product Offered
11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Eurogentec Main Business Overview
11.13.5 Eurogentec Latest Developments
11.14 HJB
11.14.1 HJB Company Information
11.14.2 HJB Antibody and Recombinant Protein CDMO Product Offered
11.14.3 HJB Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 HJB Main Business Overview
11.14.5 HJB Latest Developments
11.15 Bibo Pharma
11.15.1 Bibo Pharma Company Information
11.15.2 Bibo Pharma Antibody and Recombinant Protein CDMO Product Offered
11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Bibo Pharma Main Business Overview
11.15.5 Bibo Pharma Latest Developments
11.16 MabPlex International
11.16.1 MabPlex International Company Information
11.16.2 MabPlex International Antibody and Recombinant Protein CDMO Product Offered
11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 MabPlex International Main Business Overview
11.16.5 MabPlex International Latest Developments
11.17 Genscriptprobio
11.17.1 Genscriptprobio Company Information
11.17.2 Genscriptprobio Antibody and Recombinant Protein CDMO Product Offered
11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Genscriptprobio Main Business Overview
11.17.5 Genscriptprobio Latest Developments
11.18 Vetter
11.18.1 Vetter Company Information
11.18.2 Vetter Antibody and Recombinant Protein CDMO Product Offered
11.18.3 Vetter Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Vetter Main Business Overview
11.18.5 Vetter Latest Developments
11.19 Etinpro (Beijing) Co
11.19.1 Etinpro (Beijing) Co Company Information
11.19.2 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product Offered
11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Etinpro (Beijing) Co Main Business Overview
11.19.5 Etinpro (Beijing) Co Latest Developments
11.20 Boehringer Ingelheim BioXcellence
11.20.1 Boehringer Ingelheim BioXcellence Company Information
11.20.2 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product Offered
11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Boehringer Ingelheim BioXcellence Main Business Overview
11.20.5 Boehringer Ingelheim BioXcellence Latest Developments
11.21 Lonza
11.21.1 Lonza Company Information
11.21.2 Lonza Antibody and Recombinant Protein CDMO Product Offered
11.21.3 Lonza Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.21.4 Lonza Main Business Overview
11.21.5 Lonza Latest Developments
11.22 3SBio Inc
11.22.1 3SBio Inc Company Information
11.22.2 3SBio Inc Antibody and Recombinant Protein CDMO Product Offered
11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.22.4 3SBio Inc Main Business Overview
11.22.5 3SBio Inc Latest Developments
11.23 Porton
11.23.1 Porton Company Information
11.23.2 Porton Antibody and Recombinant Protein CDMO Product Offered
11.23.3 Porton Antibody and Recombinant Protein CDMO Revenue, Gross Margin and Market Share (2019-2024)
11.23.4 Porton Main Business Overview
11.23.5 Porton Latest Developments
12 Research Findings and Conclusion

List of Tables
Table 1. Antibody and Recombinant Protein CDMO Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Antibody CDMO
Table 3. Major Players of Recombinant Protein CDMO
Table 4. Antibody and Recombinant Protein CDMO Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 5. Global Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 6. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Table 7. Antibody and Recombinant Protein CDMO Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 9. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Table 10. Global Antibody and Recombinant Protein CDMO Revenue by Players (2019-2024) & ($ Millions)
Table 11. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Player (2019-2024)
Table 12. Antibody and Recombinant Protein CDMO Key Players Head office and Products Offered
Table 13. Antibody and Recombinant Protein CDMO Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Antibody and Recombinant Protein CDMO Market Size by Regions 2019-2024 & ($ Millions)
Table 17. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Regions (2019-2024)
Table 18. Global Antibody and Recombinant Protein CDMO Revenue by Country/Region (2019-2024) & ($ millions)
Table 19. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Country/Region (2019-2024)
Table 20. Americas Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & ($ Millions)
Table 21. Americas Antibody and Recombinant Protein CDMO Market Size Market Share by Country (2019-2024)
Table 22. Americas Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 23. Americas Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Table 24. Americas Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 25. Americas Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Table 26. APAC Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & ($ Millions)
Table 27. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Region (2019-2024)
Table 28. APAC Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 29. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Table 30. APAC Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 31. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Table 32. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2019-2024) & ($ Millions)
Table 33. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Country (2019-2024)
Table 34. Europe Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 35. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Table 36. Europe Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 37. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Table 38. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Region (2019-2024) & ($ Millions)
Table 39. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Region (2019-2024)
Table 40. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Type (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Table 42. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Application (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Table 44. Key Market Drivers & Growth Opportunities of Antibody and Recombinant Protein CDMO
Table 45. Key Market Challenges & Risks of Antibody and Recombinant Protein CDMO
Table 46. Key Industry Trends of Antibody and Recombinant Protein CDMO
Table 47. Global Antibody and Recombinant Protein CDMO Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 48. Global Antibody and Recombinant Protein CDMO Market Size Market Share Forecast by Regions (2025-2030)
Table 49. Global Antibody and Recombinant Protein CDMO Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 50. Global Antibody and Recombinant Protein CDMO Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 51. Batavia Biosciences Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 52. Batavia Biosciences Antibody and Recombinant Protein CDMO Product Offered
Table 53. Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Batavia Biosciences Main Business
Table 55. Batavia Biosciences Latest Developments
Table 56. Grifols Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 57. Grifols Antibody and Recombinant Protein CDMO Product Offered
Table 58. Grifols Main Business
Table 59. Grifols Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 60. Grifols Latest Developments
Table 61. Cerbios-Pharma SA Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 62. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Offered
Table 63. Cerbios-Pharma SA Main Business
Table 64. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 65. Cerbios-Pharma SA Latest Developments
Table 66. HALIX Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 67. HALIX Antibody and Recombinant Protein CDMO Product Offered
Table 68. HALIX Main Business
Table 69. HALIX Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 70. HALIX Latest Developments
Table 71. Biovian Oy Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 72. Biovian Oy Antibody and Recombinant Protein CDMO Product Offered
Table 73. Biovian Oy Main Business
Table 74. Biovian Oy Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 75. Biovian Oy Latest Developments
Table 76. Catalent Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 77. Catalent Antibody and Recombinant Protein CDMO Product Offered
Table 78. Catalent Main Business
Table 79. Catalent Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 80. Catalent Latest Developments
Table 81. Goodwin Biotechnology Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 82. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product Offered
Table 83. Goodwin Biotechnology Main Business
Table 84. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 85. Goodwin Biotechnology Latest Developments
Table 86. Merck Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 87. Merck Antibody and Recombinant Protein CDMO Product Offered
Table 88. Merck Main Business
Table 89. Merck Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 90. Merck Latest Developments
Table 91. Hangzhou Hs-biopharm Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 92. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product Offered
Table 93. Hangzhou Hs-biopharm Main Business
Table 94. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 95. Hangzhou Hs-biopharm Latest Developments
Table 96. Wuxibiologics Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 97. Wuxibiologics Antibody and Recombinant Protein CDMO Product Offered
Table 98. Wuxibiologics Main Business
Table 99. Wuxibiologics Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 100. Wuxibiologics Latest Developments
Table 101. Bioinnobio Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 102. Bioinnobio Antibody and Recombinant Protein CDMO Product Offered
Table 103. Bioinnobio Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 104. Bioinnobio Main Business
Table 105. Bioinnobio Latest Developments
Table 106. Thousand Oaks Biopharmaceuticals Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 107. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product Offered
Table 108. Thousand Oaks Biopharmaceuticals Main Business
Table 109. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 110. Thousand Oaks Biopharmaceuticals Latest Developments
Table 111. Eurogentec Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 112. Eurogentec Antibody and Recombinant Protein CDMO Product Offered
Table 113. Eurogentec Main Business
Table 114. Eurogentec Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 115. Eurogentec Latest Developments
Table 116. HJB Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 117. HJB Antibody and Recombinant Protein CDMO Product Offered
Table 118. HJB Main Business
Table 119. HJB Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 120. HJB Latest Developments
Table 121. Bibo Pharma Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 122. Bibo Pharma Antibody and Recombinant Protein CDMO Product Offered
Table 123. Bibo Pharma Main Business
Table 124. Bibo Pharma Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 125. Bibo Pharma Latest Developments
Table 126. MabPlex International Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 127. MabPlex International Antibody and Recombinant Protein CDMO Product Offered
Table 128. MabPlex International Main Business
Table 129. MabPlex International Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 130. MabPlex International Latest Developments
Table 131. Genscriptprobio Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 132. Genscriptprobio Antibody and Recombinant Protein CDMO Product Offered
Table 133. Genscriptprobio Main Business
Table 134. Genscriptprobio Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 135. Genscriptprobio Latest Developments
Table 136. Vetter Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 137. Vetter Antibody and Recombinant Protein CDMO Product Offered
Table 138. Vetter Main Business
Table 139. Vetter Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 140. Vetter Latest Developments
Table 141. Etinpro (Beijing) Co Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 142. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product Offered
Table 143. Etinpro (Beijing) Co Main Business
Table 144. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 145. Etinpro (Beijing) Co Latest Developments
Table 146. Boehringer Ingelheim BioXcellence Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 147. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product Offered
Table 148. Boehringer Ingelheim BioXcellence Main Business
Table 149. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 150. Boehringer Ingelheim BioXcellence Latest Developments
Table 151. Lonza Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 152. Lonza Antibody and Recombinant Protein CDMO Product Offered
Table 153. Lonza Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 154. Lonza Main Business
Table 155. Lonza Latest Developments
Table 156. 3SBio Inc Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 157. 3SBio Inc Antibody and Recombinant Protein CDMO Product Offered
Table 158. 3SBio Inc Main Business
Table 159. 3SBio Inc Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 160. 3SBio Inc Latest Developments
Table 161. Porton Details, Company Type, Antibody and Recombinant Protein CDMO Area Served and Its Competitors
Table 162. Porton Antibody and Recombinant Protein CDMO Product Offered
Table 163. Porton Main Business
Table 164. Porton Antibody and Recombinant Protein CDMO Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 165. Porton Latest Developments

List of Figures
Figure 1. Antibody and Recombinant Protein CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Antibody and Recombinant Protein CDMO Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Antibody and Recombinant Protein CDMO Sales Market Share by Country/Region (2023)
Figure 8. Antibody and Recombinant Protein CDMO Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Type in 2023
Figure 10. Antibody and Recombinant Protein CDMO in Pharmaceutical Company
Figure 11. Global Antibody and Recombinant Protein CDMO Market: Pharmaceutical Company (2019-2024) & ($ Millions)
Figure 12. Antibody and Recombinant Protein CDMO in Biotechnology Company
Figure 13. Global Antibody and Recombinant Protein CDMO Market: Biotechnology Company (2019-2024) & ($ Millions)
Figure 14. Antibody and Recombinant Protein CDMO in Generic Company
Figure 15. Global Antibody and Recombinant Protein CDMO Market: Generic Company (2019-2024) & ($ Millions)
Figure 16. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Application in 2023
Figure 17. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Player in 2023
Figure 18. Global Antibody and Recombinant Protein CDMO Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Antibody and Recombinant Protein CDMO Market Size 2019-2024 ($ Millions)
Figure 20. APAC Antibody and Recombinant Protein CDMO Market Size 2019-2024 ($ Millions)
Figure 21. Europe Antibody and Recombinant Protein CDMO Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size 2019-2024 ($ Millions)
Figure 23. Americas Antibody and Recombinant Protein CDMO Value Market Share by Country in 2023
Figure 24. United States Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Region in 2023
Figure 29. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Type in 2023
Figure 30. APAC Antibody and Recombinant Protein CDMO Market Size Market Share by Application in 2023
Figure 31. China Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Country in 2023
Figure 38. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Figure 39. Europe Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Figure 40. Germany Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Antibody and Recombinant Protein CDMO Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 54. APAC Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 55. Europe Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 57. United States Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 58. Canada Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 61. China Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 62. Japan Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 63. Korea Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 65. India Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 66. Australia Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 67. Germany Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 68. France Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 69. UK Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 70. Italy Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 71. Russia Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 72. Spain Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 75. Israel Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Antibody and Recombinant Protein CDMO Market Size 2025-2030 ($ Millions)
Figure 78. Global Antibody and Recombinant Protein CDMO Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Antibody and Recombinant Protein CDMO Market Size Market Share Forecast by Application (2025-2030)
"

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted